IN8bio
$1.39
35
-$0.01-1.07% Today
Statistics
Day High
1.46
Day Low
1.35
52W High
5.82
52W Low
1.17
Volume
8,158
Avg. Volume
73,326
Mkt Cap
6.42M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
7MayExpected
Expected EPS
-0.5438
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-60.87MNet Income
Analyst Ratings
$6.00Average Price Target
The highest estimate is 6.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow INAB. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Novartis
NVS
Mkt Cap237.61B
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Allogene Therapeutics
ALLO
Mkt Cap275.13M
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
Pfizer
PFE
Mkt Cap140.15B
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
About
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Show more...
CEO
Mr. Tai-Wei Ho
Employees
18
Country
US
ISIN
US45674E2081
Listings
0 Comments
Share your thoughts
FAQ
What is IN8bio stock price today?▼
The current price of INAB is $1.39 USD — it has decreased by -1.07% in the past 24 hours. Watch IN8bio stock price performance more closely on the chart.
What is IN8bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange IN8bio stocks are traded under the ticker INAB.
Is IN8bio stock price growing?▼
INAB stock has fallen by -2.72% compared to the previous week, the month change is a -15.88% fall, over the last year IN8bio has showed a +738.22% increase.
What is IN8bio market cap?▼
Today IN8bio has the market capitalization of 6.42M
When is the next IN8bio earnings date?▼
IN8bio is going to release the next earnings report on May 07, 2026.
What were IN8bio earnings last quarter?▼
INAB earnings for the last quarter are -0.45 USD per share, whereas the estimation was -0.64 USD resulting in a +29.74% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is IN8bio revenue for the last year?▼
IN8bio revenue for the last year amounts to 0 USD.
What is IN8bio net income for the last year?▼
INAB net income for the last year is -60.87M USD.
How many employees does IN8bio have?▼
As of April 02, 2026, the company has 18 employees.
In which sector is IN8bio located?▼
IN8bio operates in the Health Care sector.
When did IN8bio complete a stock split?▼
The last stock split for IN8bio was on June 06, 2025 with a ratio of 1:30.
Where is IN8bio headquartered?▼
IN8bio is headquartered in New York, US.